Skip to content

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Sustainability Reports

The company is a science-driven biotechnology firm dedicated to the development of innovative immuno-oncology therapies. It focuses on research and development pipelines that target both the innate and adaptive immune systems to treat cancer and autoimmune diseases.

Sector: Manufacturing

Country: China

Exchange: Hong Kong Stock Exchange

LEI: 25490040OVM0N5Z3GG60

FIGI: BBG00QKHV748

6 reports from 2023 to 2025